Evogene (EVGN) Return on Sales (2012 - 2026)

Evogene (EVGN) posted Return on Sales of 0.0% for Q1 2026, up 182.26% sequentially from 0.0% in Q4 2025, and up 1.0% YoY from 0.0% in Q1 2025.

Evogene (EVGN) Return on Sales (2012 - 2026) Analysis & Trends

Evogene has reported Return on Sales for 15 years, with the latest figure at 0.0% in Q1 2026.

Quarterly Return on Sales rose 1.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.04% (up 5.0% YoY) and the FY2025 annual result came in at 0.01%, up 2.0% from the prior year.
Return on Sales advanced to 0.0% in Q1 2026 per EVGN's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.25% in Q3 2025 and troughed at 0.38% in Q1 2022.
A 5-year average of 0.07% and a median of 0.01% in 2025 frame the typical range for Return on Sales.
The widest YoY moves for Return on Sales: up 40 bps in 2022, down 17 bps in 2022.
Over 5 years, Return on Sales stood at 0.06% in 2022, then tumbled by 119 bps to 0.13% in 2023, then jumped by 95 bps to 0.01% in 2024, then surged by 92 bps to 0.0% in 2025, then surged by 182 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.25% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.00%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	0.00%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	0.00%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.00%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.00%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.00%
10	Evogene	4.38 Mn	4.38 Mn	204,000.00	-0.18%

Download Data